161 related articles for article (PubMed ID: 25224572)
41. The impact of the global bacille Calmette-Guérin shortage on treatment patterns: population-based data.
Perera M; Papa N; Christidis D; McGrath S; Manning T; Roberts M; Bolton D; Lawrentschuk N; Sengupta S
BJU Int; 2018 Feb; 121(2):169-172. PubMed ID: 29072817
[No Abstract] [Full Text] [Related]
42. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.
Hinotsu S; Akaza H; Naito S; Ozono S; Sumiyoshi Y; Noguchi S; Yamaguchi A; Nagamori S; Terai A; Nasu Y; Kume H; Tomita Y; Tanaka Y; Samma S; Uemura H; Koga H; Tsushima T
BJU Int; 2011 Jul; 108(2):187-95. PubMed ID: 21176079
[TBL] [Abstract][Full Text] [Related]
43. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
[TBL] [Abstract][Full Text] [Related]
44. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
45. Prognostic value of p53 overexpression in bladder tumors treated with Bacillus Calmette-Guerin.
Peyromaure M; Ravery V
Expert Rev Anticancer Ther; 2002 Dec; 2(6):667-70. PubMed ID: 12503212
[TBL] [Abstract][Full Text] [Related]
46. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.
Witjes JA; Dalbagni G; Karnes RJ; Shariat S; Joniau S; Palou J; Serretta V; Larré S; di Stasi S; Colombo R; Babjuk M; Malmström PU; Malats N; Irani J; Baniel J; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Pisano F; Gontero P; Sylvester R
Urol Oncol; 2016 Nov; 34(11):484.e19-484.e25. PubMed ID: 27639776
[TBL] [Abstract][Full Text] [Related]
47. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
48. Re: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.
Klotz L
J Urol; 2000 Nov; 164(5):1666. PubMed ID: 11025741
[No Abstract] [Full Text] [Related]
49. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.
Morales A; Herr H; Steinberg G; Given R; Cohen Z; Amrhein J; Kamat AM
J Urol; 2015 Apr; 193(4):1135-43. PubMed ID: 25286009
[TBL] [Abstract][Full Text] [Related]
51. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
52. Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73.
Cai T; Luciani LG; Malossini G
Eur Urol; 2010 Jun; 57(6):e57; author reply e58-9. PubMed ID: 20227819
[No Abstract] [Full Text] [Related]
53. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
Gaya JM; Palou J; Algaba F; Arce J; Rodríguez-Faba O; Villavicencio H
Can J Urol; 2010 Oct; 17(5):5370-6. PubMed ID: 20974029
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
[TBL] [Abstract][Full Text] [Related]
56. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
Järvinen R; Kaasinen E; Rintala E; Group TF
Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
[TBL] [Abstract][Full Text] [Related]
57. [The BCG as coadjuvant in the treatment of bladder carcinoma].
Rodrigues Netto N; Caserta Lemos G; de Belis N
Arch Esp Urol; 1979; 32(5):417-26. PubMed ID: 507944
[TBL] [Abstract][Full Text] [Related]
58. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
[TBL] [Abstract][Full Text] [Related]
59. Reply to Donald L. Lamm and Nilay M. Gandhi's letter to the editor re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85.
Ehdaie B; Sylvester R; Herr HW
Eur Urol; 2014 Jan; 65(1):e7. PubMed ID: 24113320
[No Abstract] [Full Text] [Related]
60. Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.
Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
J Urol; 2011 Jan; 185(1):67-71. PubMed ID: 21074202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
